Tissue Regenix (GB:TRX) has released an update.
Tissue Regenix Group PLC, a leader in regenerative medical devices, successfully passed all resolutions at their Annual General Meeting, with overwhelming shareholder support. Their patented decellularisation technology, dCELL®, continues to innovate in the medical field, addressing vital needs in various medical procedures. The company’s acquisition of CellRight Technologies in 2017 has further strengthened its position in the regenerative medicine space.
For further insights into GB:TRX stock, check out TipRanks’ Stock Analysis page.
